To mark Rare Disease Day on 28 February, we celebrated the team, patients and partners behind DETEMINE, the UK’s first national precision medicine trial for rare cancers, which is run by our Centre for Drug Development.

DETERMINE is led by chief investigator Matt Krebs (University of Manchester) with his team at The Christie, along with paediatric lead Lynley Marshall (Royal Marsden), translational lead Gary Middleton and statistical lead Lucinda Billingham (University of Birmingham).

From winning a Bionow Award to treating its 100th patient, read about the milestones this landmark trial has hit on the journey to providing much needed treatment options for people with rare cancers.

Join our collaborative research seminar organised between our Manchester, City of London and Cambridge Centres on 31 March to promote inclusive research activities.

This series spotlights various topics related to equity, diversity and inclusivity in cancer research. The next seminar focuses on our communities, and how researchers can work effectively with public contributors to achieve excellent research outcomes.

Keynote speaker Lorraine Turner (The Christie NHS Foundation Trust) specialises in participatory research and co-develops research studies to better understand the perceptions of cancer and clinical trials among underserved groups.

This free webinar is open to all researchers, you do not need to be based at one of our centres.